Skip to content

Asset Entities ASST Medical Device — Transaction costs

Other segment segments

Corporate & Other
$6.53M
Asset Management
$0

Similar metrics at other companies

KEE
KEELTransaction Cost
$975K
KEE
KEELTransaction Cost
$975K
Surgery Partners, Inc. logo
SGRYSurgical Facilities — Transaction and integration costs
$15.6M-36.8%
LifeStance Health Group logo
LFSTTransaction Costs
$544K
Artivion logo
AORTMedical devices — Total cost of products and preservation services
$29.7M+17.6%
Lithium Americas logo
LACTransaction Costs
$1M-76.7%

Other financials

Income statement

See full
Revenue$2.8M+1,516%
Operating income-$313.1M-7,588%
Net income-$265.9M-6,993%
EPS (diluted)-$4.53-175%

Balance sheet

See full
Cash & equivalents$95.1M+982%
Total debt$3.4M
Total equity$714.8M+3,548%
Total assets$1.1B+21,931%

Cash flow

See full
Operating cash flow-$31.0M-455%
CapEx--100%
Free cash flow-$31.0M-450%

Valuation

See full
Market cap$1.02B+1,127%
Enterprise value$932M
P/S118.1×

Profitability

See full
Operating margin-6,563%-18,545pp
Net margin-8,022.9%-20,291pp
FCF margin-3,856.7%

Returns & leverage

See full
Return on equity-189.4%+139pp
Debt / equity
Current ratio11.4×+1.7×

Where this comes from

Reported directly by Asset Entities in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationAcquisitionRelatedCosts.

The official record: Asset Entities’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Asset Entities's medical device — transaction costs.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Asset Entities's medical device — transaction costs?
Asset Entities (ASST) reported medical device — transaction costs of $0 in Q1 2026.
What does medical device — transaction costs mean?
Includes the direct costs associated with completing specific business transactions, such as acquisitions or financing activities, within the medical device segment. Tracking these costs is essential for understanding the efficiency of capital deployment and inorganic growth strategies.